Journal
TRENDS IN ENDOCRINOLOGY AND METABOLISM
Volume 31, Issue 7, Pages 525-535Publisher
CELL PRESS
DOI: 10.1016/j.tem.2020.02.005
Keywords
-
Categories
Funding
- NHMRC [APP1142398]
- CSL
- National Heart foundation [101951]
Ask authors/readers for more resources
Clonal hematopoiesis of indeterminate potential (CHIP), defined as a clone of hematopoietic cells consisting of a single acquired mutation during a lifetime, has recently been discovered to be a major risk factor for atherosclerotic cardiovascular disease (CVD). As such, this phenomenon has sparked interest into the role that these single mutations may play in CVD. Atherosclerotic CVD is a complex disease and we have previously shown that atherosclerosis can be accelerated by metabolic- or autoimmune-related risk factors such as diabetes, obesity, and rheumatoid arthritis. In this review, we discuss the role of CHIP, the interplay between CHIP and metabolic diseases, as well as how metabolism of hematopoietic stem cells (HSCs) could regulate CHIP-related HSC fate.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available